EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes

Wen Ye iD, Christopher J Becker iD, Jing Li, Shihchen Kuo, Xiaqing Jiang iD, William H Herman iD, Lynda D Lisabeth iD, Lewis B Morgenstern iD

Stroke · 2026-06 · 57 (6) · 1737-1746

DOI: 10.1161/strokeaha.126.055187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke, 2026-06. Verfasst von Wen Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics (W.Y., J.L.), University of Michigan School of Public Health, Ann Arbor. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Stroke, Primary Prevention. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Much attention has focused on reducing prehospital delay among patients with acute ischemic stroke (AIS) to facilitate delivery of highly effective but time-sensitive treatments. The relative benefits and cost-effectiveness of minimizing treatment delays versus more fully implementing primary prevention measures for AIS are unclear in high-risk populations, including US adults with type 2 diabetes. METHODS: We used data from the National Health and Nutrition Examination Survey (2015–2018) to identify US adults ≥45 years of age with type 2 diabetes and no prior stroke (N=1232). Stroke incidence, quality-adjusted life-years, and healthcare costs over 10 years were projected using the Michigan Model for Diabetes, a validated microsimulation model. Three scenarios were compared: (1) status quo (50% of patients with AIS arrive within 24 hours; 28% within 3.5 hours; average population-level adherence to preventive strategies); (2) optimized hospital arrival time (all patients with stroke arriving within 24 hours [50%] arrive within 3.5 hours); and (3) full implementation of 4 primary prevention strategies (blood pressure control, statin therapy, smoking cessation, and aspirin). Analyses were conducted from a health system/payer perspective. RESULTS: The study population has a weighted mean age of 64 and 56.1% males. Improving hospital arrival times to 50% within 3.5 hours was cost-effective (incremental cost-effectiveness ratio: $41 624 per quality-adjusted life-year gained), preventing 10 900 cases of stroke-related major disability and 6700 stroke deaths, and yielding an increase of 18 300 quality-adjusted life-years nationwide at a cost of $0.63 billion over 10 years. Universal adoption of primary prevention strategies averted 68 900 cases of stroke-related major disability and 61 900 stroke deaths with a gain of 1 418 000 quality-adjusted life-years nationwide and savings of $13.4 billion over 10 years. CONCLUSIONS: Although reducing prehospital delay in AIS treatment may be cost-effective, broad adoption of recommended primary prevention strategies for AIS in US adults with type 2 diabetes confers substantially greater health and economic benefits. The significance of preventive medicine, such as controlling hypertension and dyslipidemia, smoking cessation, and aspirin therapy, cannot be overstated for individuals with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisDiabetes Mellitus, Type 2StrokePrimary PreventionIschemic StrokeEmergency Medical ServicesTime-to-TreatmentHumansCost-Effectiveness AnalysisMaleFemaleMiddle AgedAgedUnited StatesTreatment DelayQuality-Adjusted Life YearsHealth Care Costs

Stichwörter der Autor:innen

blood pressurehospitalsischemic strokeprimary preventiontreatment delay

Autor:innen und Institutionen

  • Department of Biostatistics (W.Y., J.L.), University of Michigan School of Public Health, Ann Arbor.
  • Department of Neurology (C.J.B., L.B.M.), University of Michigan Medical School, Ann Arbor.
  • Department of Internal Medicine (S.K., W.H.H.), University of Michigan Medical School, Ann Arbor.
  • Department of Psychology and Behavior Science, University of California San Francisco (X.J.).
  • Department of Epidemiology (W.H.H., L.D.L.), University of Michigan School of Public Health, Ann Arbor.

ORCID-Profile: Wen Ye, Christopher J Becker, Xiaqing Jiang, William H Herman, Lynda D Lisabeth, Lewis B Morgenstern

Förderung

  • NIDDK NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Ye, W., Becker, C. J., Li, J., Kuo, S., Jiang, X., Herman, W. H., Lisabeth, L. D., & Morgenstern, L. B. (2026). Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes. Stroke, 57(6), 1737-1746. https://doi.org/10.1161/strokeaha.126.055187

Vancouver

Ye W, Becker CJ, Li J, Kuo S, Jiang X, Herman WH, et al. Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes. Stroke. 2026;57(6):1737-1746. doi:10.1161/strokeaha.126.055187

BibTeX
@article{Ye2026,
  author = {Ye, Wen and Becker, Christopher J and Li, Jing and Kuo, Shihchen and Jiang, Xiaqing and Herman, William H and Lisabeth, Lynda D and Morgenstern, Lewis B},
  title = {Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes},
  journal = {Stroke},
  year = {2026},
  volume = {57},
  number = {6},
  pages = {1737--1746},
  doi = {10.1161/strokeaha.126.055187}
}
Kostenlos starten →